http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 15 May 2026 06:31:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Globe+Newswire/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Globe+Newswire/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Globe+Newswire/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Globe+Newswire/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Globe+Newswire/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX